LAS VEGAS — At the American Academy of Ophthalmology, Phillip C. Hoopes, MD, discusses 3-month data on the first 32 patients who were implanted with the Kamra inlay (Acufocus) at Hoopes Vision.
Uncategorized
Uncategorized
Speaker: Prevention key to managing neurotrophic keratopathy
LAS VEGAS — Prevention is key to managing varicella zoster virus neurotrophic keratopathy, according to a speaker here. “This is the diabetic foot ulcer of the eye,” Todd Margolis, MD, PhD, said at Cornea Subspecialty Day preceding the American Academy of Ophthalmology meeting. Neurotrophic keratopathy is characterized by decreased corneal sensation and poor corneal healing.
Uncategorized
Early BCVA response may predict long-term outcomes of anti-VEGF treatment for DME
LAS VEGAS — Best corrected visual acuity response after three anti-VEGF injections for 12 weeks may be a strong predictor of long-term best corrected visual acuity response in patients with diabetic macular edema patients, according to a presentation here.In an assessment of Protocol I data from the DRCR.net, Pravin U. Dugel, MD, presented long-term treatment outcomes of anti-VEGF therapy in patients with diabetic macular edema at the American Academy of Ophthalmology annual meeting.
Uncategorized
Oral acyclovir may be used to prevent recurrence of herpes simplex keratitis
LAS VEGAS — Recurrence of herpes simplex keratitis is commonly associated with corneal scarring and poor corneal graft survival. Early diagnosis and treatment helps prevent permanent corneal scarring caused by the virus’ lytic reaction and its immune-mediated response, according to a speaker here. Daily applications of trifluridine 1% solution or ganciclovir 0.15% are commonly used to treat acute herpetic epithelial keratitis and have been shown to shorten the clinical course, Natalie Afshari, MD, said here at Cornea Subspecialty Day preceding the American Academy of Ophthalmology annual meeting.
Uncategorized
VIDEO: Co-founder of Novaliq gives business update
LAS VEGAS — At the Ophthalmology Innovation Summit, Bernhard Günther, managing director, CEO and co-founder of Novaliq, shares recent business updates, including plans for entering into a phase 2 clinical trial on CyclASol (cyclosporine solution) in 2016.
Uncategorized
VIDEO: Global marketing director introduces intense pulsed light device
LAS VEGAS — At the Ophthalmology Innovation Summit, Itay Mayer, global marketing director of Lumenis Vision, talks about how ophthalmologists can use the intense pulsed light, a device using optimal pulsed technology.